期刊文献+

玻璃体切除术联合雷珠单抗治疗黄斑水肿观察

Observation of vitrectomy combined with Ranibizumab for macular edema
分享 导出
摘要 目的评价25G玻璃体切除联合术前玻璃体内注射雷珠单抗治疗黄斑水肿的效果。方法回顾性分析2013年1月至2017年9月郑州市第二人民医院120例(120眼)黄斑水肿的资料,患者随机分为两组。对照组60例,采用25G玻璃体切除手术,观察组60例,25G玻璃体切除术前联合玻璃体内注射雷珠单抗。术后观察6个月。结果术前视力两组间差异无统计学意义(t=0.073,P=0.943);术后1周、2周、1个月及3个月视力,两组相比差异有统计学意义(F=55.420,P=0.000);治疗前黄斑部视网膜厚度两组间差异无统计学意义(t=1.297,P=0.211);术后1周、2周、1个月及3个月黄斑部视网膜厚度两组间差异有统计学意义(F=153.634,P=0.000);手术时间:观察组(44.20±6.44)min,对照组(62.44±8.87)min,两组间差异有统计学意义(t=4.900,P=0.000);两组术中出血情况比较,两组间差异有统计学意义(x2=4.236,P=0.040)。结论25G玻璃体切除术联合术前玻璃体内注射雷珠单抗治疗黄斑水肿,能够迅速改善患者视力,快速消退水肿,缩短术中操作时间及减少并发症。 Objective To evaluate the effect of 25G vitrectomy combined with intravitreal injection of Ranibizumab for the treatment of macular edema. Methods The data of 120 eyes of 120 patients from Jan. 2013 to Sep. 2017 were analyzed retrospectively. The patients were divided randomly into 2 groups. The control group, 60 patients, underwent 25G vitrectomy, and the observation group, 60 cases, received 25G vitrectomy after Ranibizumab intravitreal injection. The efficacy of two groups were observed. Results The difference of visual acuity before operation was not statistically significant (t=0. 073, P=0. 943), at 1, 2 weeks, 1 and 3 months after operation, the difference of visual acuity were statistically significant ( F =55. 420, P=0. 000) between the two groups. The difference of retinal thickness of macular before operation was not statistically significant (t=1. 297, P=0. 211). At 1, 2 weeks, 1 and 3 months after operation, the difference were statistically significant between the two groups (F=153. 634, P=0. 000). Operation time were (44. 20 ± 6. 44) min in the observation group, and (62. 44 ± 8. 87) min in the control group. The difference was statistically significant between the two groups (t=4. 900, P=0. 000). The difference of intraoperative bleeding was statistically significant between the two groups (χ2 =4. 236, P =0. 040). Conclusion The treatment of 25G vitrectomy combined with Ranibizumab intravitreal injection before operation for macular edema, can improve visual acuity fastly, regresse of macular edema rapidly and reduce of intraoperative operating time and complications.
作者 刘建君 周尚昆 王骞 陈鹏 肖燕 Liu Jianjun;Zhou Shang kun;Wang Qian;Chen Peng;Xiao Yan(Department of Ophthalmology,The Second Municipal Hospital of Zhengzhou,Zhengzhou Eye Hospital,Zhengzhou Institute of Ophthalmology,Zhengzhou 450000,China;Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)
出处 《中华眼外伤职业眼病杂志》 2018年第11期855-858,共4页 Journal of Injuries and Occupational Diseases of the Eye with Ophthalmic Surgeries
关键词 水肿 黄斑 玻璃体切除术 25G 雷珠单抗 玻璃体内注射 Edema,macular Vitrectomy,25G Ranibizumab,intravitreal injection
作者简介 通信作者:周尚昆,Email:zhshk198@163.com.
  • 相关文献

参考文献5

二级参考文献58

  • 1惠延年.糖尿病视网膜病变并发症的玻璃体手术治疗和手术并发症控制[J].中华眼底病杂志,2007,23(4):231-233. 被引量:34
  • 2中华医学会眼科学分会眼底病学组.糖尿病视网膜病变分期标准[J].眼底病,1985,1:42. 被引量:10
  • 3Crawford TN,Alfaro DV -rd, Kerrison JB,et al. Diabetic retinopa- thy and angiogenesis[ J]. Curr Diabetes Rev,2009,5 ( 1 ) :8-13. 被引量:1
  • 4Mandelcom MS, Blankenship G, Machemer R. Pars plana vitrecto- my for the management of sever diabetic retinopathy [ J ]. Am J Ophthalmol, 1976,81 ( 5 ) :561-70. 被引量:1
  • 5Aldebasi YH, Rahmani AH, Khan AA, et al. The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy[ J]. Int J Clin Exp Med,2013,6(4) :239-51. 被引量:1
  • 6Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal rteovascularization [ J]. Ret- ina,2011,31 (5) :871-9. 被引量:1
  • 7Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease [ J ]. Prog Retin Eye Res, 2008,27 ( 4 ) : 331-71. 被引量:1
  • 8Chong V. Biological, preclinical and clinical characteristics of in- hibitors of vascular endothelial growth factors [ J ]. Ophthalmologi- ca,2012,227 Suppl ( 1 ) :2-10. 被引量:1
  • 9Jardeleza MS, Miller JW. Review of anti-vegf therapy in prolifera- tive diabetic retinopathy [ J ]. Semin Ophthalmol, 2009,24 ( 2 ) : 87-92. 被引量:1
  • 10Bakri SJ, Snyder MR, Reid JM, et al. Pharmaeokineties of intravit- real ranibizumab (lucentis) [ J ]. Ophthalmology, 2007,114 ( 12 ) : 2179-82. 被引量:1

共引文献36

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈